The Association of the British Pharmaceutical Industry (ABPI) represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
The BIA is at the forefront of UK bioscience, serving as its voice, connecting individuals and organisations, from SMEs, including innovative start-ups, to multi-national companies, helping to shape the future of the sector.
Covers the field of biological sciences, including medicine. It indexes journal articles, meeting and conference reports, books and patents. Consider searching here for information on new research, pharmaceuticals and emerging technologies.
Systematic reviews of social, behavioural and educational interventions.
Decisions about which medical devices and drugs to use are crucial to the quality and sustainability of health care in Canada. Access to evidence-based information is key to making informed decisions that harness the benefits of technology while getting the best value from every health dollar.
The Institut national d’excellence en santé et en services sociaux was created on January 19, 2011. It succeeded the Conseil du médicament and the Agence d’évaluation des technologies et des modes d’intervention en santé (AETMIS). INESSS’s mission is to promote clinical excellence and the efficient use of resources in the health and social services sector. At the heart of the mission, INESSS assesses, in particular, the clinical advantages and the costs of the technologies, medications and interventions used in health care and personal social services. It issues recommendations concerning their adoption, use and coverage by the public plan, and develops guides to clinical practice in order to ensure their optimal use.
Includes the PDQ (Physician Data Query) database of cancer prevention, screening, genetics, diagnostic and treatment information, cancer clinical trials, statistics and patient guides.
Clinical trials, protocols and other information, including the metaRegister of Controlled Trials (mRCT) – an international database combining multiple registries of ongoing controlled trials in healthcare.
A clinical trials listing service and information source for the clinical trial industry.
This UK centre provides several databases.
The Cumulated Index to Nursing and Allied Health Literature, CINAHL is also useful for coverage of the literature on occupational therapy, physiotherapy, and alternative medicine
A clinical therapy resource of regularly updated evidence-based summaries, including a useful drug names table.
A database of clinical trials compiled by the US National Institutes of Health.
The official guide for conducting Cochrane systematic reviews.
Updated quarterly. The source for quality, systematic reviews of health care interventions; includes several databases. A subscription is required for full access (most health libraries have subscriptions; some countries have open access agreements with the publisher to make it freely available in their country).
Welcome to the website of the Common European Drug Database (CEDD) project which is an initiative of the National Health Insurance Fund Administration of Hungary to make prices of pharmaceuticals easily available for the public of Europe. In the present version of the website you can search and compare the prices of Austrian, Czech, Finnish, Hungarian, Irish, Lithuanian, Norwegian, Polish, Slovenian and Slovakian pharmaceuticals according to product names or ATC codes.
We secure UK and global prosperity by promoting and financing international trade and investment, and championing free trade.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 37 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
A database covering international literature in the fields of biomedical sciences and pharmacology.
EMIG is the trade association in the UK that represents the interests of small to medium-sized pharmaceutical companies. EMIG member companies range from start-ups, whose prime focus is R&D, to highly developed businesses delivering essential products to patients, while continuing to invest heavily in the fight against disease. This rich blend of companies enables EMIG to uniquely understand and address the myriad challenges facing pharmaceutical innovation and commercialisation in the UK. EMIG is a democratic organisation, with one vote for each full member company, irrespective of size. EMIG policy is ratified by the membership at our AGM and reported on/refined at our Quarterly Meetings throughout the year. EMIG enables pharmaceutical SMEs to have an influence on the policies that determine success or failure in the UK.
Database of the Educational Resources Information Center includes health-related educational information.
EUCOPE provides a platform for discussion for pharmaceutical entrepreneurs. On a regular basis owners and CEOs of pharmaceutical companies and associations discuss solutions to improve the quality of life for patients and to strengthen the competitiveness of the European pharmaceutical industry.
Timelines for all procedures This page lists the timetables for the submission, start and finish dates of procedures, as well as other interim dates and milestones that occur during the various procedures. Timetables are categorised according to the type of procedure (e.g. full applications, extensions and variations, as well as response timetables). The dates for submission, start of the procedure and plenary meetings of the Committee for Medicinal Products for Human Use (CHMP), the Pharmacovigilance Risk Assessment Committee (PRAC) and the Committee for Advanced Therapies (CAT) are generally fixed, but the other dates may be subject to adjustment until the CHMP reaches the adoption of the final opinion for the individual application. At the start of the procedure, the Agency will notify the applicant of the adopted final timetable in writing.
HAS is an independent public authority that contributes to the regulation of health system quality. It carries out its tasks in the field of evaluation of health products, professional practices, the organization of health care and public health.
The Federal Joint Committee (G-BA) is the highest decision-making body of the joint self-government of physicians, dentists, hospitals and health insurance funds in Germany. It issues directives for the benefit catalogue of the statutory health insurance funds (GKV) for more than 70 million insured persons and thus specifies which services in medical care are reimbursed by the GKV. In addition, the G-BA specifies measures for quality assurance in inpatient and outpatient areas of the health care system.
National Prices of Medicines A source of national pricing information for 35 countries – states which category of price, for example reimbursement, ex-factory, patient
Assessments of health care interventions and a useful project methodology guide for health technology assessment.
The NIHR Innovation Observatory works closely with industry partners reporting about new drugs, devices and diagnostics to NICE and the NIHR. NICE will only consider reviewing a technology once it has first been through an initial filtering process managed by the NIHR Innovation Observatory. Therefore, if you are a company that wants to access the NICE technology appraisal process for a new product or a new use for a currently licensed or registered product, then please contact NIHRIO.
Listings of clinical trials registries in different medical specialties.
An international organisation promoting the science of pharmacoeconomics and health outcomes research Includes a section: Pharmacoeconomic Guidelines Around the World.
The Authority has a statutory remit to evaluate the clinical and cost-effectiveness of health technologies and provide advice arising out of the evaluation to the Minister for Health and Children and the Health Service Executive (HSE). The primary audience for health technology assessments (HTAs) conducted by the Authority is therefore decision makers within the publicly-funded healthcare system. It is recognised that the findings of any such HTA may also have implications for other key stakeholders in the Irish healthcare system. These include patient groups, the general public, clinicians, other healthcare providers, academic groups and the manufacturing industry.
The National Centre for Pharmacoeconomics conducts the health technology assessment (HTA) of pharmaceutical products for the Health Service Executive (HSE) in Ireland in collaboration with the HSE Corporate Pharmaceutical Unit (HSE-CPU). The aim of the centre is to promote expertise in Ireland for the advancement of the discipline of pharmacoeconomics through practice, research and education.
Includes Science Citation Index Expanded, Social Sciences Citation Index, Current Contents Connect, and other databases. These databases cover literature in the fields of science and technology, social sciences and humanities.
MAP offer an online resource that guides you through market access across the EU, empowering subscribers to develop their own pricing and reimbursement strategies.
MAP offers an up to date, validated, web based subscription service, which acts as a ‘virtual’ expert to help you achieve pricing and reimbursement across the EU.
Medicines and Healthcare Products Regulatory Agency: The UK agency which regulates drugs and health technologies.
PDQ, part of the Cancer.gov website, includes a database of ongoing and completed cancer trials, and information on cancer prevention, diagnosis and treatment.
Quality, accessibility and affordability are the cornerstones of the Dutch health care system. The Health Care Insurance Board has an important position in this system: we ensure that these pillars form a strong foundation. Thus we represent the interests of everyone under the Insurance Act and the Exceptional Medical Expenses Act are entitled to care.
Access to many US NLM databases, including: ClinicalTrials.gov, MEDLINE/PubMed, LOCATORplus, MEDLINEplus, DIRLINE, Meeting Abstracts, TOXLINE Special and HSRProj.
WHO medicines, prices and funding – provides some source data for the prices of medicines in over 50 national organisations based in 35 countries.
Ovid helps researchers, librarians, clinicians, and other healthcare professionals find important medical information so that they can make critical decisions to improve patient care, enhance ongoing research, and fuel new discoveries. We offer a market-leading medical research platform of premium aggregated content and productivity tools that make it easy to quickly search information and make informed decisions on patient care, quality, and clinical outcomes.
The US National Library of Medicine (NLM)’s free search interface provides access to over 15 million citations covering biomedical literature back to the 1950’s in MEDLINE, PreMEDLINE (in process citations), OLDMEDLINE, and publisher supplied records.
Additional databases are available through commercial vendors, such as Dialog.
Spanish Ministry of Health.
The Dental and Pharmaceutical Benefits Agency, TLV, is a central government agency whose remit is to determine whether a pharmaceutical product or dental care procedure shall be subsidised by the state. We also contribute to quality service and accessibility of pharmacies.
The UK national office for HTA website has a useful database of published and in progress research and the full text of their assessment reports.
Extensive and wide range of resources including Guideline Finder, Protocol and Care Pathways, and Specialists Libraries to support healthcare-related decisions. http://www.evidence.nhs.uk/
On 1 April 2005 NICE joined with the Health Development Agency to become the new National Institute for Health and Clinical Excellence (also to be known as NICE). Guidance and technology appraisal reports, and patient information for the UK NHS.
Scottish guidelines and guideline development methods.
The remit of the Scottish Medicines Consortium (SMC) is to provide advice to NHS Boards and their Area Drug and Therapeutics Committees (ADTCs) across Scotland about the clinical and cost-effectiveness of all newly licensed medicines, all new formulations of existing medicines and new indications for established products (licensed from January 2002).
The All Wales Medicines Strategy Group (AWMSG) was established in 2002, as a statutory advisory Welsh Assembly-sponsored public body under the 1977 NHS Act, to provide advice on medicines management and prescribing to the Welsh Government’s Minister for Health and Social Services in an effective, efficient and transparent manner.
Single Horizon Scanning Database for New Drugs in Development in the UK UK PharmaScan is a secure horizon scanning database populated with information on new medicines in development from up to three years before their launch in the UK or start of phase III clinical development, whichever is the earlier. This central repository provides up-to-date information, such as clinical trial and regulatory information, to national horizon scanning groups and approved NHS organisations that have a role in supporting NHS planning, or provide advice and guidance to the NHS. The resource will help ensure earlier and more effective decision making and faster uptake of innovative new medicines for the patients who need them.